TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01460368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00973674
Drug: Premarin IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of Premarin IV
Study: NCT00973674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of Placebo
Study: NCT00071396
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
Study: NCT01212107
Drug: FGF Receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2874455 administered orally.
Study: NCT01212107
Drug: Phosphate Binders
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03503136
Drug: docetaxel, nedaplatin, and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
Study: NCT03503136
Drug: docetaxel, cisplatin, and fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Study: NCT03503136
Drug: docetaxel, cisplatin, and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
Study: NCT03503136
Drug: docetaxel, nedaplatin, and fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Study: NCT04148391
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules.
Study: NCT00005878
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00810693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo tid orally for 12 weeks
Study: NCT00891293
Drug: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
Normalized name: omega-3 acid ethyl esters (USP) 1000 MG [Lovaza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
Study: NCT01768767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00769522
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
Study: NCT04882241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04882241
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablets
Study: NCT04882241
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT04162665
Drug: Standard of care chemotherapy regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommendations are CAPOX, FOLFOX, or FLT.
Study: NCT02572609
Drug: Mucosolvan ® adult syrup
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01783054
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
Study: NCT00295893
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02127710
Drug: AZD6094
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
Study: NCT00295893
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02990533
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03680092
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).
Study: NCT03680092
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11
Study: NCT02979197
Drug: OE 200 mg celecoxib capsule
Normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02979197
Drug: Matched placebo for OE celecoxib capsule
Normalized name: celecoxib Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03661645
Drug: 10 mg IV dexamethasone & 6 day oral methylprednisolone taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day.~Drug:10 mg intravenous (IV) dexamethasone
Study: NCT02081183
Drug: Cyclophosphamide, Maintenance Phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-1 g/m\^2 IV pulse once every 3 months
Study: NCT02081183
Drug: Cyclophosphamide, Induction Phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 - 1 g/m\^2 IV pulse once per month
Study: NCT00003927
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003927
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02631109
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2 day1
Study: NCT05576675
Drug: sufentanil + nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 100 μ g + nalbuphine 40 mg
Study: NCT05576675
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufentanil 200 μ g
Study: NCT00795847
Drug: Preminent (losartan/hydrochlorothiazide combination drug)
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
Study: NCT00202059
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03867383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 milliliters normal saline
Study: NCT00036413
Drug: TCH346
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01174121
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X2 days over 1 hr.
Study: NCT01626378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
Study: NCT03610360
Drug: MesoPher
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Masophen PM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
Study: NCT02213354
Drug: MF59
Normalized name: vaccine adjuvant emulsion MF59C.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
Study: NCT00561769
Drug: Norditropin pen
Normalized name: somatropin Pen Injector [Norditropin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 IU per day
Study: NCT01821027
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
Study: NCT02003209
Drug: Aromatase Inhibition Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given at the investigator's discretion
Study: NCT03415828
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradiscal infiltration of steroids
Study: NCT01861327
Drug: CO2
Normalized name: CO2 (ISBT symbol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbon dioxide (CO2) as arterial contrast media
Study: NCT02592694
Drug: cocktail
Normalized name: Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
Study: NCT04143893
Drug: Optimal medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with cardiogenic shock who received optimal medical treatment including vasopressor
Study: NCT01879514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
Study: NCT01203631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose administered subcutaneously (s.c., under the skin)
Study: NCT01470937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: acarbose placebo
Study: NCT03227328
Drug: concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitor:~* palbociclib~* ribociclib~* abemaciclib~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant
Study: NCT03227328
Drug: chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Chemotherapy regimens will be classified as:~* anthracycline + taxane,~* taxane,~* anthracycline,~* capecitabine / fluoropyrimidines,~* others.~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant
Study: NCT04638400
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin administered daily for 6 weeks
Study: NCT01805440
Drug: Uridine
Normalized name: Uridine
DrugBank: Uridine (DB02745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uridine is the active treatment in this clinical trial.
Study: NCT01805440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo is the inactive treatment comparator in this clinical trial.
Study: NCT00261183
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03804008
Drug: Ultrasound-guided corticosteroid injection
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
Study: NCT02493725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03911713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to IVA.
Study: NCT03911713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos matched to VX-561.
Study: NCT01173939
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
Study: NCT01173939
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
Study: NCT02219438
Drug: Basal
Normalized name: Basaljel
Approvals — FDA: no, EMA: no, PMDA: no
Description: An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
Study: NCT01931592
Drug: ESBL eradication regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
Study: NCT01931592
Drug: Placebo ESBL eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
Study: NCT04644003
Drug: STP1
Normalized name: TRACHEAL SUCTION SET 14FR M#DYNCSTP14TH
Approvals — FDA: no, EMA: no, PMDA: no
Description: STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor
Study: NCT04644003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication (capsule and tablet) identical in appearance to active medication
Study: NCT00482313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT01745328
Drug: LVX-AMX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
Study: NCT01745328
Drug: TCM
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject is treated with TCM for 4 weeks.
Study: NCT01745328
Drug: LVX-AMX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with placebo from 2 to 4 weeks.
Study: NCT02398656
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
Study: NCT01928446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets will be administered for the duration of follow-up (1 year).
Study: NCT03449706
Drug: Early combination anti-retroviral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
Study: NCT04097145
Drug: Optimal Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy alone in patients with tricuspid regurgitation
Study: NCT03285672
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1
Study: NCT01006460
Drug: Rhodiola rosea, L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Capsules twice a day
Study: NCT01006460
Drug: Placebo - dark brown sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules twice a day
Study: NCT00902668
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01999153
Drug: 20 mL topically used during alginate dressing NAROPEINE
Normalized name: DRESSING,ALGINATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL topically used during alginate dressing
Study: NCT01999153
Drug: 20 mL topically used during alginate dressing NaCl
Normalized name: DRESSING,ALGINATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL topically used during alginate dressing
Study: NCT02024529
Drug: 4 mL Injection of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL Injection of Placebo
Study: NCT00100178
Drug: Mycophenolate mofeteil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00100178
Drug: Placebo control for Mycophenolate mofeteil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo pills taken orally
Study: NCT00491764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 24 weeks.
Study: NCT01691274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, twice a day, 14 days
Study: NCT03660345
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ziv-Aflibercept
Study: NCT01108120
Drug: continuous intra-femoral thrombolysis group
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
Study: NCT01108120
Drug: Conventional therapy group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
Study: NCT00648856
Drug: Zoloft® Tablets 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT00881673
Drug: AL38583 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic
Study: NCT00881673
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL38583 Vehicle
Study: NCT01604044
Drug: Meropur 150 a day
Approvals — FDA: no, EMA: no, PMDA: no
Description: one subcutaneous injection a day
Study: NCT03385096
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
Study: NCT01680887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03239184
Drug: Life information rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT00004006
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004006
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02660190
Drug: hexaminoavolunate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00682721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo two pills once daily
Study: NCT00322556
Drug: Immunoglobulins Intravenous (Human)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
Study: NCT00751218
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, once daily for 28 days
Study: NCT03428607
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6738 160mg QD
Study: NCT03678883
Drug: Doxorubicin.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
Study: NCT03269669
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03269669
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01318642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
Study: NCT04155697
Drug: 2% Chlorohexidine Gluconate soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
Study: NCT04155697
Drug: 62% ethyl alcohol-based hand sanitizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds